Very Low Dose Quillivant XR + Low Dose Quillivant XR + Moderate Dose Quillivant XR
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
ADHD
Conditions
ADHD, Autism
Trial Timeline
Sep 1, 2014 → Oct 1, 2016
NCT ID
NCT02255565About Very Low Dose Quillivant XR + Low Dose Quillivant XR + Moderate Dose Quillivant XR
Very Low Dose Quillivant XR + Low Dose Quillivant XR + Moderate Dose Quillivant XR is a approved stage product being developed by Pfizer for ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT02255565. Target conditions include ADHD, Autism.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02255565 | Approved | Completed |
Competing Products
20 competing products in ADHD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine | Eli Lilly | Approved | 85 |
| Strattera (atomoxetine) | Eli Lilly | Approved | 85 |
| Atomoxetine + placebo | Eli Lilly | Approved | 85 |
| Atomoxetine Hydrochloride + placebo | Eli Lilly | Approved | 85 |
| atomoxetine (Strattera) | Eli Lilly | Approved | 85 |
| Atomoxetine + stimulants (any approved ADHD medication) | Eli Lilly | Pre-clinical | 23 |
| dasotraline + Placebo | Sumitomo Pharma | Phase 3 | 77 |
| dasotraline | Sumitomo Pharma | Phase 1 | 33 |
| dasotraline 4mg | Sumitomo Pharma | Phase 3 | 77 |
| AZD1446 + AZD1446 + AZD1446 + Placebo | AstraZeneca | Phase 2 | 52 |
| Placebo + AZD3480 + AZD3480 | AstraZeneca | Phase 2 | 52 |
| MK0249 + Concerta (methylphenidate) + Placebo | Merck | Phase 2 | 52 |
| Focalin XR | Novartis | Phase 3 | 77 |
| Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo | Novartis | Approved | 85 |
| Dexmethylphenidate HCl extended-release capsules | Novartis | Phase 3 | 77 |
| Methylphenidate hydrochloride | Novartis | Phase 3 | 77 |
| Focalin XR | Novartis | Phase 3 | 77 |
| methylphenidate HCl ERCT + Placebo | Pfizer | Approved | 84 |
| methylphenidate HCl ERCT | Pfizer | Approved | 84 |
| Brexpiprazole | Lundbeck | Phase 1 | 30 |